• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Half of Cost Burden of Urological Diseases Borne by Medicare

Publication
Article
Drug Benefit TrendsDrug Benefit Trends Vol 20 No 4
Volume 20
Issue 4

Currently, an estimated 26 million persons in the United States have a urological disorder, according to a newly released government-funded report. Bladder, prostate, and other urinary tract diseases in US adults cost almost $11 billion annually (2000 data), with Medicare's share exceeding $5.4 billion, according to the study by Litwin and colleagues funded by the NIH.

Currently, an estimated 26 million persons in the United States have a urological disorder, according to a newly released government-funded report. Bladder, prostate, and other urinary tract diseases in US adults cost almost $11 billion annually (2000 data), with Medicare's share exceeding $5.4 billion, according to the study by Litwin and colleagues funded by the NIH.

The 5 most costly urological diseases, which account for $9.1 billion, were urinary tract infection (UTI) ($3.5 billion), urolithiasis (kidney stones) ($2 billion), prostate cancer ($1.3 billion), bladder cancer ($1.2 billion), and benign prostatic hyperplasia (BPH) ($1.1 billion). Medicare's share of the expenditures associated with these diseases was $1.4 billion for UTI, $834 million for urolithiasis, $927 million for prostate cancer, $719 million for bladder cancer, and $776 million for BPH (Figure 1). The estimated annual costs for privately insured persons for these 5 urological diseases were $4403, $4472, $7019, $9585, and $1536, respectively (Figure 2).

Figure 1. The cost burden for Medicare of urological diseases was half of total medical expenditures in 2000. Source: Litwin MS et al.

Urologic Diseases in America.

Washington, DC: National Institute of Diabetes and Digestive and Kidney Diseases; 2007.

 

Figure 2. Estimated annual health care costs associated with urological cancers are significantly higher than those for more common urological diseases, such as urinary tract infections, among privately insured US persons aged 18 to 64 years. Source: Litwin MS et al. Urologic Diseases in America; 2007.

UTI is a common diagnosis among women, particularly those aged 18 to 29 years (Figure 3). Of the $3.5 billion in medical expenditures for UTI, $2.5 billion was spent on treating nearly 12.8 million UTIs in women; the remaining $1 billion was spent on treating approximately 2 million UTIs in men. Annual health care expenditures for men with a UTI were $5544 compared with $2715 for men without a UTI. The difference in costs was much smaller for women: $5407 for those with a UTI versus $3833 for those who did not have a UTI.

 

Figure 3. In 2000, 10.8% of US women aged 18 years and older self-reported at least 1 urinary
tract infection (UTI) in the preceding 12 months. Source: Litwin MS et al.

Urologic Diseases in
America;

2007.

 

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
© 2024 MJH Life Sciences

All rights reserved.